Inzy earnings
WebINZY Complete Inozyme Pharma Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Web12 apr. 2024 · Check if INZY Stock has a Buy or Sell Evaluation. INZY Stock Price (NASDAQ), Forecast, Predictions, ... The upcoming earnings date for Inozyme Pharma, Inc. is 2024-05-09 00:00:00. Click to get the best stock tips daily for …
Inzy earnings
Did you know?
WebINZY Stock 12 Months Forecast. $15.25. (178.28% Upside) Based on 4 Wall Street analysts offering 12 month price targets for Inozyme Pharma in the last 3 months. The average … Web6 apr. 2024 · The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. Sector Health Care Industry Biotechnology Employees 56 Founded …
WebInozyme Pharma Reports Full Year 2024 Financial Results and Provides Business Highlights. - Founding CEO, Axel Bolte, MSc, MBA, to retire; Douglas A. Treco, Ph.D., to … Web13 apr. 2024 · We are developing INZ-701, an enzyme therapy, to address pathologic mineralization and intimal proliferation which can drive morbidity and mortality in these severe diseases. INZ-701 is currently in Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency. View Corporate Presentation Stock Quote Change
Web11 apr. 2024 · BOSTON, April 11, 2024 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical- stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Douglas A. Treco, Ph.D., the company’s chief executive officer and chairman … WebInozyme Pharma Inc. analyst ratings, historical stock prices, earnings estimates & actuals. INZY updated stock price target summary. Dow Jones, a News Corp company About WSJ
Web20 feb. 2024 · INZY has an estimated long-term growth rate of 16.6%. Inozyme Pharma’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, with the average surprise ...
Web13 apr. 2024 · Inozyme (INZY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. 3 weeks ago - Zacks … findlaw brand advocateWeb16 mrt. 2024 · This suggests that analysts have very recently bumped up their estimates for INZY, giving the stock a Zacks Earnings ESP of +12.11% heading into earnings season. Inozyme Pharma, Inc. Price... findlaw bankruptcy attorney san diegoWeb27 mrt. 2024 · Inozyme Pharma, Inc. (NASDAQ:INZY – Get Rating) – Equities researchers at Wedbush upped their Q1 2024 earnings estimates for shares of Inozyme Pharma in a report issued on Wednesday, March 22nd. era martin waverly ohioWebINZY - Inozyme Pharma, Inc. Stock Price and Quote TIP: Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools. × publish chart save to portfolio create alert compare perf. Candle - advanced Intraday Daily Weekly Draw Fullscreen Settings INZY - Stock Price Chart INZY [NASD] Inozyme Pharma, Inc. findlaw california casesWebOn Invalid Date, Inozyme Pharma (NASDAQ: INZY) reported Q4 2024 earnings per share (EPS) of -$0.42, up 46.84% year over year. Total Inozyme Pharma earnings for the quarter were -$18.54 million. In the same quarter last year, Inozyme Pharma's earnings per share (EPS) was -$0.79. findlaw california cases and codesWeb29 mrt. 2024 · Inozyme Pharma, Inc. (NASDAQ:INZY – Get Rating) – Jefferies Financial Group issued their Q1 2024 earnings estimates for shares of Inozyme Pharma in a research note issued on Wednesday, March 22nd.Jefferies Financial Group analyst S. Jeong anticipates that the company will earn ($0.44) per share for the quarter. Jefferies … findlaw benson and bingham 11441 allertonWeb12 apr. 2024 · Inozyme Pharma Inc., whose market valuation is $224.17 million at the time of this writing, is expected to release its quarterly earnings report May 08, 2024 – May 12, 2024. Investors’ optimism about the company’s current quarter earnings report is understandable. eram chateauroux